268.80

0.57% 1.52

After Hours: 276.00 7.20 +2.68%

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $268.80, with a volume of 402.80K. It is up +0.57% in the last 24 hours and up +46.40% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$267.28

Open:

$263.98

24h Volume:

402.80K

Relative Volume:

0.41

Market Cap:

$6.72B

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-29.31

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

+8.39%

1M Performance:

+46.40%

6M Performance:

+496.94%

1Y Performance:

+278.59%

1-Day Range:

$263.84

$274.35

1-Week Range:

$251.00

$278.44

52-Week Range:

$26.70

$278.44

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	268.80	6.68B	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

Dec 13, 2025

(PRAX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com

Dec 13, 2025

Dec 12, 2025

Praxis Precision Medicines Plans New Drug Application - The Globe and Mail

Dec 12, 2025

Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 - Yahoo Finance

Dec 12, 2025

Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating - marketscreener.com

Dec 12, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 12, 2025

Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance

Dec 12, 2025

Dec 11, 2025

Praxis Precision Medicines updates clinical trial design and regulatory plans - Investing.com

Dec 11, 2025

Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - MSN

Dec 11, 2025

Praxis Precision Medicines Confirms FDA Filing Path for New Drug Application of Relutrigine in Early 2026 - Quiver Quantitative

Dec 11, 2025

TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN

Dec 11, 2025

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 - Yahoo Finance

Dec 11, 2025

TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment - Insider Monkey

Dec 11, 2025

HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 11, 2025

Dec 10, 2025

Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN

Dec 10, 2025

Stempoint Capital LP Takes $1.36 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 10, 2025

Dec 09, 2025

PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus

Dec 09, 2025

Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative

Dec 09, 2025

Praxis Precision Medicines announces alignment with FDA - marketscreener.com

Dec 09, 2025

PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus

Dec 09, 2025

Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan

Dec 09, 2025

Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq

Dec 09, 2025

PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Eastern Progress

Dec 09, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive - ts2.tech

Dec 09, 2025

Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 09, 2025